Clinical trial

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

NCT04346225

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Hyperpolarized C13 Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Magnetic Resonance Imaging (MRI) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

Design: INTERVENTIONAL · Status: SUSPENDED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusSUSPENDED

Study typeINTERVENTIONAL

Start date2020-07-16

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Advanced Prostate Carcinomaunresolved

Interventions

Hyperpolarized C13DRUG

Magnetic Resonance Imaging (MRI)PROCEDURE

Sponsors & collaborators

Ivan de Kouchkovsky, MDlead sponsor

National Cancer Institute (NCI)collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)collaborator

Mapped research locations

San FranciscoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04346225 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.